| Symbol | ACB |
|---|---|
| Name | AURORA CANNABIS INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Medicinal Chemicals & Botanical Products |
| Address | 2207 90B STREET SW, EDMONTON, A0 T6X 1V8 |
| Telephone | 604-362-5207 |
| Fax | — |
| — | |
| Website | https://www.auroramj.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael 71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries. Additional info from NASDAQ: |
Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company
Read moreAurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year
Read moreAurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis
Read moreAurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03522467 | Cannabis Oil for Pain Effectiveness | Phase2 | Cancer | Unknown | 2018-07-25 | 2020-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| MRCP001 | DRUG | Phase PHASE2 | Cancer | UNKNOWN | NCT03522467 |